Current Headlines
-
Takeda Announces U.S. FDA Approval Of Supplemental New Drug Application (sNDA) For ICLUSIG (Ponatinib) In Adult Patients With Newly Diagnosed Ph+ ALL
3/19/2024
Takeda today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for ICLUSIG (ponatinib) for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy.
-
DNAnexus Adds NVIDIA NIM And CUDA-X Microservices To Precision Health Data Cloud To Accelerate Drug Discovery And Improve Patient Care
3/19/2024
DNAnexus, Inc., the provider of the Precision Health Data Cloud, today announced that it is integrating new NVIDIA NIM and CUDA-X microservices.
-
Cognizant To Apply Generative AI To Enhance Drug Discovery For Pharmaceutical Clients With NVIDIA BioNeMo
3/19/2024
Cognizant (NASDAQ: CTSH) is advancing the application of generative AI (gen AI) technology with the NVIDIA BioNeMo platform to solve complex challenges of drug discovery in the life sciences industry, such as improving productivity in the development process and increasing the speed at which new, life-saving treatments can be brought to market.
-
Journey Medical Corporation Announces U.S. FDA Acceptance Of New Drug Application For DFD-29 For The Treatment Of Rosacea
3/18/2024
Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, announced today that the FDA has accepted the Company’s New Drug Application (“NDA”) for DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) for the treatment of inflammatory lesions and erythema of rosacea in adults.
-
Sanyou Bio And BioGeometry Join Forces To Create A Next-Generation Antibody Drug Discovery Platform Driven By AIGC
3/18/2024
Recently, BioGeometry and Sanyou Bio jointly announced the signing of a strategic partnership agreement.
-
Samsung Invests In BrickBio To Develop Advanced Molecules And Therapies Using Protein Engineering Technology For Antibody-Drug Conjugates (ADC)
3/18/2024
Samsung Life Science Fund, created jointly between Samsung Biologics (KRX: 207940.KS), Samsung Bioepis, and Samsung C&T (KRX: 028260.KS), and managed by Samsung Ventures, and BrickBio, Inc. announced Samsung's investment in BrickBio, a preclinical-stage biopharmaceutical company focused on developing precision biologics using an expanded genetic code.
-
Selvita Launches Biologic Drug Discovery And Development Services
3/18/2024
Selvita S.A. announced today a strategic initiative to significantly expand its services portfolio and enter the field of biologic drug discovery and development, by adding comprehensive therapeutic antibody discovery and development capabilities to its portfolio.
-
U.S. Food And Drug Administration (FDA) Has Accepted The New Drug Application (NDA) For Ensartinib
3/13/2024
Xcovery Holdings, Inc., an oncology focused pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for ensartinib, an Anaplastic Lymphoma Kinase (ALK) inhibitor for the treatment of adult patients with metastatic ALK-positive non-small cell lung cancer (NSCLC).
-
Poseida Therapeutics Announces FDA Orphan Drug Designation Granted To P-BCMA-ALLO1 For The Treatment Of Multiple Myeloma
3/13/2024
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for the treatment of multiple myeloma to P-BCMA-ALLO1, a novel BCMA-targeted allogeneic, T stem cell memory (TSCM)-rich chimeric antigen receptor (CAR)-T therapy candidate.
-
Allumiqs And Prolytix Form Strategic Partnership To Accelerate Drug Discovery And Development
3/13/2024
Allumiqs and Prolytix, today announced their long-term, strategic partnership focused on delivering collaborative and integrated solutions to help customers optimize drug development pipelines. Together the partners empower customers with bioanalytical solutions to advance drug candidates from the early R&D phases through to lot release.